Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Subcutaneous drug delivery has emerged as a promising and viable alternative to intravenous administration. The rising demand for subcutaneous drug delivery is attributed to the rapid development of biologics. Moreover, the subcutaneous route of administration is generally preferred, as it enables self-medication, improves quality of life, and thus reduces healthcare costs.

Furthermore, convenience and safety for both patients and medical professionals offered by subcutaneous devices are major factors leading to growth of the global subcutaneous drug delivery market. According to the World Health Organization, 2014, around 2 million healthcare professionals suffered from infectious diseases as result of needlestick injuries, globally. The retractable nature of prefilled syringes help to overcome this problem, thereby acting as an ideal device to reduce the occurrence of needlestick injuries.

The global subcutaneous drug delivery market size is estimated to be valued at US$ 9,111.6 million in 2020 and is expected to exhibit a CAGR of 9.7% over the forecast period (2020-2027).

Figure 1. Global Subcutaneous Drug Delivery Market Share (%), by Usability, 2020

Subcutaneous Drug Delivery  | Coherent Market Insights

Adoption of inorganic growth strategies by key players is expected to propel the market growth over the forecast period

Increasing focus of manufacturers on adoption of inorganic growth strategies such as collaboration and partnership, in order to strengthen their product portfolio of subcutaneous drug delivery systems is expected to drive the market growth over the forecast period. For instance, in October 2017, EVER Neuro Pharma GmbH acquired PHARMAGEN CZ s.r.o, a company that specializes in injectable segment, located in Slovakia, Europe.

Through this acquisition, EVER expanded its market presence in Europe and leveraged its specialty injectable portfolio.

Increasing focus of preventing the needlestick injuries to bolster the global subcutaneous drug delivery market growth

Needlestick injuries with injection needles and lancing devices are a key concern of patients with diabetes. Insulin syringe needlestick injuries is a percutaneous wound injury caused by the needle tips and can occur while using, handling, disassembling or disposing needles and syringes. Increasing awareness regarding safety and concern about needlestick injuries are major factors driving growth of the subcutaneous drug delivery market.

Preference for safety injection devices is increasing among healthcare professionals and manufacturers, as these devices decrease the chances of needlestick injuries. For instance, WHO recommended the use of safety syringes with sharp injury protection (SIP) in order to prevent needlestick injuries. Moreover, in May 2017, Innovative Neurons LLC announced its plan to commercialize its patented auto retractable multi-needle syringe known as FAST (fast, accessible, safe, and technology), to decrease needlestick injuries. In 2016, Nipro Medical Corporation launched 'SafeTouch' safety needle, which protects patients from needlestick injuries.

Global Subcutaneous Drug Delivery Market Restraint

The unavailability of approved products due to increasing number of product recalls by various developers is a factor hindering growth of the global subcutaneous drug delivery market. For instance, on May 18, 2020, Bausch & Lomb UK Limited announced a recall of Emerade 500 microgram auto-injectors, owing to error in one component of auto injector, which caused the failure to activate the pen and deliver adrenaline drug. Moreover, in April 2018, Becton Dickson and Company announced recall of PosiFlush Heaparin Lock Flush Syringe and Prefilled normal saline syringe, owing to contamination with Serratia marcescens bacterium.

In March, 2017, Mylan N.V. and its manufacturing partner for EpiPen Auto-injector voluntary recalled the EpiPen and EpiPen Jr auto-injectors distributed in the U.S. and markets in Europe, Asia, North, and South America in consultation with the U.S. Food and Drug Administration (FDA). The recall was initiated as a result of the failure of the device to activate in emergency due to a potential defect.

request-sample

Subcutaneous Drug Delivery Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 9,111.6 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 9.7% 2027 Value Projection: US$ 17,445.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Usability: Disposable, Reusable.
  • By Disease Indication: Auto-immune Disorders, Neurological Disorders, Oncology Disorders, Hormonal Disorders, Allergy & Infectious Disorders, Ophthalmic Disorders, Others.
  • By Delivery Type:
    • Prefilled Syringe
    • Autoinjector: Spring Type, Motorized Type, Wearable Type.
    • Prefilled Pen: Disposable, Reusable.
    • Vial (Syringe), Pump and Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc., Novartis International AG, Insulet Corporation, West Pharmaceutical Services, Inc., and Gerresheimer AG

Growth Drivers:
  • Increasing prevalence of arthritis, multiple sclerosis, and diabetes
  • Increasing adoption of prefilled syringes
  • Prevention of needlestick injuries
Restraints & Challenges:
  • Product recalls

Global Subcutaneous Drug Delivery Market – Impact of Coronavirus (Covid-19) Pandemic

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 5 million infected individuals worldwide as of June 2020.

COVID-19 can affect the economy in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. are being disrupted due to global lockdown while many countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

The stockpiling of subcutaneous or oral formulations due to the lockdown may cause a spike in demand for certain products. According to an article published in the Center for Biosimilars (American Journal of Managed Care), on February 27, 2020, manufacturers such as Novartis AG who have manufacturing facilities in Austria, Europe, are particularly at risk on the supply side.

Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global subcutaneous drug delivery market during the forecast period.

Figure 2. Global Subcutaneous Drug Delivery Market Value Share (US$ Mn), by Region, 2020

Subcutaneous Drug Delivery  | Coherent Market Insights

Initiatives by companies to make autoinjectors available to patients suffering from anaphylaxis and other disease conditions are driving growth of the North America subcutaneous drug delivery market. For instance, Mylan N.V. provides discount cards to epinephrine buyers, and offers discount of up to US$ 300 on the branded version of EpiPen and up to US$ 25 off on the approved generic version of EpiPen. Manufacturers are focused on combatting the product shortage issue in the region. For instance, in August 2018, Kaleo confirmed sufficient availability of AUVI-Q for anaphylaxis treatment.

Key Players

Major players operating in the global subcutaneous drug delivery market include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc., Novartis International AG, Insulet Corporation, West Pharmaceutical Services, Inc., and Gerresheimer AG.

The market comprises products, which are available in reusable and disposable form. Disposable segment is expected to witness growth, owing to significant increase in self-administration of drugs to treat chronic diseases. Moreover, the shift from vial-and-syringe format, which is prone to dosing errors and low patient-compliance rates, to prefilled syringes that enable the use of disposable and single-use syringes already filled with a prescribed unit dose of medication, is expected to drive the market growth.

Market Dynamics

Technological innovations and developments in prefilled syringes and auto-injectors is contributing to the market growth. For instance, Gerresheimer introduced metal-free Luer Lock Gx RTF Syringe in 2017, without tungsten to create perfect primary packaging material for biotechnologically manufactured active ingredients that ideally exclude the possibility of contamination with metal. Moreover, in 2019, YpsoMed developed YpsoMate SmartPilot, a reusable attachment to its proprietary YpsoMate pen, which is designed for an easy two-step injection process. The device has a sensor and memory, which is connected with an app, which displays injection timing and doses. The pen provides audio and visual feedback to users. The app can also remind users when it is time to inject the insulin.

Key features of the study:

  • This report provides in-depth analysis of the global subcutaneous drug delivery market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global subcutaneous drug delivery market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc., Novartis International AG, Insulet Corporation, West Pharmaceutical Services, Inc., and Gerresheimer AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global subcutaneous drug delivery market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global subcutaneous drug delivery market

Detailed Segmentation:

  • Global Subcutaneous Drug Delivery Market, By Usability:
    • Disposable
    • Reusable
  • Global Subcutaneous Drug Delivery Market, By Disease Indication:
    • Auto-immune Disorders
    • Neurological Disorders
    • Oncology Disorders
    • Hormonal Disorders
    • Allergy & Infectious Disorders
    • Ophthalmic Disorders
    • Others
  • Global Subcutaneous Drug Delivery Market, By Delivery Type:
    • Prefilled Syringe
    • Autoinjector
      • Spring Type
      • Motorized Type
      • Wearable Type
    • Prefilled Pen
      • Disposable
      • Reusable
    • Vial (Syringe)
    • Pump and Others
  • Global Subcutaneous Drug Delivery Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Subcutaneous Drug Delivery Market, By Region:
    • North America
      • By Usability:
        • Disposable
        • Reusable
      • By Disease Indication:
        • Auto-immune Disorders
        • Neurological Disorders
        • Oncology Disorders
        • Hormonal Disorders
        • Allergy & Infectious Disorders
        • Ophthalmic Disorders
        • Others
      • By Delivery Type:
        • Prefilled Syringe
        • Autoinjector
          • Spring Type
          • Motorized Type
          • Wearable Type
        • Prefilled Pen
          • Disposable
          • Reusable
        • Vial (Syringe)
        • Pump and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Usability:
        • Disposable
        • Reusable
      • By Disease Indication:
        • Auto-immune Disorders
        • Neurological Disorders
        • Oncology Disorders
        • Hormonal Disorders
        • Allergy & Infectious Disorders
        • Ophthalmic Disorders
        • Others
      • By Delivery Type:
        • Prefilled Syringe
        • Autoinjector
          • Spring Type
          • Motorized Type
          • Wearable Type
        • Prefilled Pen
          • Disposable
          • Reusable
        • Vial (Syringe)
        • Pump and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Usability:
        • Disposable
        • Reusable
      • By Disease Indication:
        • Auto-immune Disorders
        • Neurological Disorders
        • Oncology Disorders
        • Hormonal Disorders
        • Allergy & Infectious Disorders
        • Ophthalmic Disorders
        • Others
      • By Delivery Type:
        • Prefilled Syringe
        • Autoinjector
          • Spring Type
          • Motorized Type
          • Wearable Type
        • Prefilled Pen
          • Disposable
          • Reusable
        • Vial (Syringe)
        • Pump and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Usability:
        • Disposable
        • Reusable
      • By Disease Indication:
        • Auto-immune Disorders
        • Neurological Disorders
        • Oncology Disorders
        • Hormonal Disorders
        • Allergy & Infectious Disorders
        • Ophthalmic Disorders
        • Others
      • By Delivery Type:
        • Prefilled Syringe
        • Autoinjector
          • Spring Type
          • Motorized Type
          • Wearable Type
        • Prefilled Pen
          • Disposable
          • Reusable
        • Vial (Syringe)
        • Pump and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Usability:
        • Disposable
        • Reusable
      • By Disease Indication:
        • Auto-immune Disorders
        • Neurological Disorders
        • Oncology Disorders
        • Hormonal Disorders
        • Allergy & Infectious Disorders
        • Ophthalmic Disorders
        • Others
      • By Delivery Type:
        • Prefilled Syringe
        • Autoinjector
          • Spring Type
          • Motorized Type
          • Wearable Type
        • Prefilled Pen
          • Disposable
          • Reusable
        • Vial (Syringe)
        • Pump and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Usability:
        • Disposable
        • Reusable
      • By Disease Indication:
        • Auto-immune Disorders
        • Neurological Disorders
        • Oncology Disorders
        • Hormonal Disorders
        • Allergy & Infectious Disorders
        • Ophthalmic Disorders
        • Others
      • By Delivery Type:
        • Prefilled Syringe
        • Autoinjector
          • Spring Type
          • Motorized Type
          • Wearable Type
        • Prefilled Pen
          • Disposable
          • Reusable
        • Vial (Syringe)
        • Pump and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Becton, Dickinson and Company*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Novo Nordisk A/S
    • Johnson & Johnson
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Amgen, Inc.
    • F. Hoffmann-La Roche AG
    • Consort Medical plc
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis International AG
    • Insulet Corporation
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Usability
      • Market Snippet, By Disease Indication
      • Market Snippet, By Delivery System
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Impact Analysis
    • Technological Evolution
    • Regulatory Scenario
    • Key Developments
    • Collaboration and Acquisition
    • Diagnosis Rate/Ratio
    • Pipeline Analysis
    • PEST Analysis
    • Reimbursement Scenario
  4. Global Subcutaneous Drug Delivery Market, Impact of COVID-19 Pandemic
    • COVID19 Impact
    • Economic Impact
    • Demand and Supply Impact Analysis
  5. Global Subcutaneous Drug Delivery Market, By Usability, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Disposable
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Reusable
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Subcutaneous Drug Delivery Market, By Disease Indication, 2016–2027 (US$ Mn)
    1. Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Auto-immune Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Neurological Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Oncology Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Hormonal Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Allergy & Infectious Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Ophthalmic Disorders
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Subcutaneous Drug Delivery Market, By Delivery System, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
    • Segment Trends
      • Prefilled Syringes
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Autoinjector
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Spring Type
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Motorized Type
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Wearable Type
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Pen Injectors
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Disposable
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Reusable
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Syringes (Injector)
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Pump & Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Global Subcutaneous Drug Delivery Market, By Distribution Channel, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  9. Global Subcutaneous Drug Delivery Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Usability, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Delivery System, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Usability, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Delivery System, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Usability, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Delivery System, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Usability, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Delivery System, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Usability, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Delivery System, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Usability, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Delivery System, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Company Profiles
      • Becton Dickinson and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Consort Medical plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Insulet Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • West Pharmaceutical Services, Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gerresheimer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 45 market data tables and 47 figures on "Global Subcutaneous Drug Delivery Market – Regional forecast to 2027”.

Frequently Asked Questions

The global subcutaneous drug delivery market size is estimated to be valued at US$ 9,111.6 million in 2020 and is expected to exhibit a CAGR of 9.7% between 2020 and 2027.
Increasing prevalence of arthritis, multiple sclerosis, and diabetes, increasing adoption of prefilled syringes, and prevention of needlestick injuries are driving growth of the global subcutaneous drug delivery market.
Autoimmune disorders segment is estimated to hold major market share in 2020, owing to rising prevalence of autoimmune diseases such as multiple sclerosis and new approvals for injector devices.
Prefilled syringes is estimated to hold major market share in the subcutaneous drug delivery market over the forecast period. The growth is expected to be driven by new product launches of prefilled syringes.
North America is expected to generate highest revenue share in 2020 in the global subcutaneous drug delivery market during the forecast period.
Product recall is a key factor hampering growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner